img

Global Oral Antiviral Medicines for COVID-19 Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global Oral Antiviral Medicines for COVID-19 Market Insights, Forecast to 2034

The global Oral Antiviral Medicines for COVID-19 market is projected to grow from US$ million in 2023 to US$ million by 2033, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Oral Antiviral Medicines for COVID-19 is estimated to increase from $ million in 2023 to reach $ million by 2033, at a CAGR of % during the forecast period of 2023 through 2033.
The China market for Oral Antiviral Medicines for COVID-19 is estimated to increase from $ million in 2023 to reach $ million by 2033, at a CAGR of % during the forecast period of 2023 through 2033.
The Europe market for Oral Antiviral Medicines for COVID-19 is estimated to increase from $ million in 2023 to reach $ million by 2033, at a CAGR of % during the forecast period of 2023 through 2033.
The global key manufacturers of Oral Antiviral Medicines for COVID-19 include Pfizer, Merck, Shionogi, Simcere Pharmaceutical, Frontier Biotechnologies and Kexing Biopharm, etc. In 2023, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Oral Antiviral Medicines for COVID-19, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2023, estimates for 2023, and projections of CAGR through 2033.
This report researches the key producers of Oral Antiviral Medicines for COVID-19, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Oral Antiviral Medicines for COVID-19, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oral Antiviral Medicines for COVID-19 sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Oral Antiviral Medicines for COVID-19 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2033. Evaluation and forecast the market size for Oral Antiviral Medicines for COVID-19 sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Merck, Shionogi, Simcere Pharmaceutical, Frontier Biotechnologies and Kexing Biopharm, etc.



By Company


Pfizer
Merck
Shionogi
Simcere Pharmaceutical
Frontier Biotechnologies
Kexing Biopharm
Segment by Type
Lagevrio
Paxlovid
Azvudine

Segment by Application


Aldult
Elder

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Oral Antiviral Medicines for COVID-19 in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Oral Antiviral Medicines for COVID-19 manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Antiviral Medicines for COVID-19 sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Oral Antiviral Medicines for COVID-19 Product Introduction
1.2 Market by Type
1.2.1 Global Oral Antiviral Medicines for COVID-19 Market Size Growth Rate by Type, 2018 VS 2023 VS 2033
1.2.2 Lagevrio
1.2.3 Paxlovid
1.2.4 Azvudine
1.3 Market by Application
1.3.1 Global Oral Antiviral Medicines for COVID-19 Market Size Growth Rate by Application, 2018 VS 2023 VS 2033
1.3.2 Aldult
1.3.3 Elder
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oral Antiviral Medicines for COVID-19 Sales Estimates and Forecasts 2018-2033
2.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Region
2.2.1 Global Oral Antiviral Medicines for COVID-19 Revenue by Region: 2018 VS 2023 VS 2033
2.2.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Region (2018-2023)
2.2.3 Global Oral Antiviral Medicines for COVID-19 Revenue by Region (2024-2033)
2.2.4 Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Region (2018-2033)
2.3 Global Oral Antiviral Medicines for COVID-19 Sales Estimates and Forecasts 2018-2033
2.4 Global Oral Antiviral Medicines for COVID-19 Sales by Region
2.4.1 Global Oral Antiviral Medicines for COVID-19 Sales by Region: 2018 VS 2023 VS 2033
2.4.2 Global Oral Antiviral Medicines for COVID-19 Sales by Region (2018-2023)
2.4.3 Global Oral Antiviral Medicines for COVID-19 Sales by Region (2024-2033)
2.4.4 Global Oral Antiviral Medicines for COVID-19 Sales Market Share by Region (2018-2033)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Oral Antiviral Medicines for COVID-19 Sales by Manufacturers
3.1.1 Global Oral Antiviral Medicines for COVID-19 Sales by Manufacturers (2018-2023)
3.1.2 Global Oral Antiviral Medicines for COVID-19 Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oral Antiviral Medicines for COVID-19 in 2023
3.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Manufacturers
3.2.1 Global Oral Antiviral Medicines for COVID-19 Revenue by Manufacturers (2018-2023)
3.2.2 Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Oral Antiviral Medicines for COVID-19 Revenue in 2023
3.3 Global Key Players of Oral Antiviral Medicines for COVID-19, Industry Ranking, 2021 VS 2023 VS 2023
3.4 Global Oral Antiviral Medicines for COVID-19 Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Oral Antiviral Medicines for COVID-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Oral Antiviral Medicines for COVID-19, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Oral Antiviral Medicines for COVID-19, Product Offered and Application
3.8 Global Key Manufacturers of Oral Antiviral Medicines for COVID-19, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Oral Antiviral Medicines for COVID-19 Sales by Type
4.1.1 Global Oral Antiviral Medicines for COVID-19 Historical Sales by Type (2018-2023)
4.1.2 Global Oral Antiviral Medicines for COVID-19 Forecasted Sales by Type (2024-2033)
4.1.3 Global Oral Antiviral Medicines for COVID-19 Sales Market Share by Type (2018-2033)
4.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Type
4.2.1 Global Oral Antiviral Medicines for COVID-19 Historical Revenue by Type (2018-2023)
4.2.2 Global Oral Antiviral Medicines for COVID-19 Forecasted Revenue by Type (2024-2033)
4.2.3 Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Type (2018-2033)
4.3 Global Oral Antiviral Medicines for COVID-19 Price by Type
4.3.1 Global Oral Antiviral Medicines for COVID-19 Price by Type (2018-2023)
4.3.2 Global Oral Antiviral Medicines for COVID-19 Price Forecast by Type (2024-2033)
5 Market Size by Application
5.1 Global Oral Antiviral Medicines for COVID-19 Sales by Application
5.1.1 Global Oral Antiviral Medicines for COVID-19 Historical Sales by Application (2018-2023)
5.1.2 Global Oral Antiviral Medicines for COVID-19 Forecasted Sales by Application (2024-2033)
5.1.3 Global Oral Antiviral Medicines for COVID-19 Sales Market Share by Application (2018-2033)
5.2 Global Oral Antiviral Medicines for COVID-19 Revenue by Application
5.2.1 Global Oral Antiviral Medicines for COVID-19 Historical Revenue by Application (2018-2023)
5.2.2 Global Oral Antiviral Medicines for COVID-19 Forecasted Revenue by Application (2024-2033)
5.2.3 Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Application (2018-2033)
5.3 Global Oral Antiviral Medicines for COVID-19 Price by Application
5.3.1 Global Oral Antiviral Medicines for COVID-19 Price by Application (2018-2023)
5.3.2 Global Oral Antiviral Medicines for COVID-19 Price Forecast by Application (2024-2033)
6 US & Canada
6.1 US & Canada Oral Antiviral Medicines for COVID-19 Market Size by Type
6.1.1 US & Canada Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2033)
6.1.2 US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2033)
6.2 US & Canada Oral Antiviral Medicines for COVID-19 Market Size by Application
6.2.1 US & Canada Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2033)
6.2.2 US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2033)
6.3 US & Canada Oral Antiviral Medicines for COVID-19 Market Size by Country
6.3.1 US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Country: 2018 VS 2023 VS 2033
6.3.2 US & Canada Oral Antiviral Medicines for COVID-19 Sales by Country (2018-2033)
6.3.3 US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Country (2018-2033)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Oral Antiviral Medicines for COVID-19 Market Size by Type
7.1.1 Europe Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2033)
7.1.2 Europe Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2033)
7.2 Europe Oral Antiviral Medicines for COVID-19 Market Size by Application
7.2.1 Europe Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2033)
7.2.2 Europe Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2033)
7.3 Europe Oral Antiviral Medicines for COVID-19 Market Size by Country
7.3.1 Europe Oral Antiviral Medicines for COVID-19 Revenue by Country: 2018 VS 2023 VS 2033
7.3.2 Europe Oral Antiviral Medicines for COVID-19 Sales by Country (2018-2033)
7.3.3 Europe Oral Antiviral Medicines for COVID-19 Revenue by Country (2018-2033)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Oral Antiviral Medicines for COVID-19 Market Size
8.1.1 China Oral Antiviral Medicines for COVID-19 Sales (2018-2033)
8.1.2 China Oral Antiviral Medicines for COVID-19 Revenue (2018-2033)
8.2 China Oral Antiviral Medicines for COVID-19 Market Size by Application
8.2.1 China Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2033)
8.2.2 China Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Oral Antiviral Medicines for COVID-19 Market Size by Type
9.1.1 Asia Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2033)
9.1.2 Asia Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2033)
9.2 Asia Oral Antiviral Medicines for COVID-19 Market Size by Application
9.2.1 Asia Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2033)
9.2.2 Asia Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2033)
9.3 Asia Oral Antiviral Medicines for COVID-19 Sales by Region
9.3.1 Asia Oral Antiviral Medicines for COVID-19 Revenue by Region: 2018 VS 2023 VS 2033
9.3.2 Asia Oral Antiviral Medicines for COVID-19 Revenue by Region (2018-2033)
9.3.3 Asia Oral Antiviral Medicines for COVID-19 Sales by Region (2018-2033)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Market Size by Type
10.1.1 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2033)
10.1.2 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2033)
10.2 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Market Size by Application
10.2.1 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2033)
10.2.2 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2033)
10.3 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Country
10.3.1 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Country: 2018 VS 2023 VS 2033
10.3.2 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Country (2018-2033)
10.3.3 Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Country (2018-2033)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Oral Antiviral Medicines for COVID-19 Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Pfizer Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Overview
11.2.3 Merck Oral Antiviral Medicines for COVID-19 Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Merck Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 Shionogi
11.3.1 Shionogi Company Information
11.3.2 Shionogi Overview
11.3.3 Shionogi Oral Antiviral Medicines for COVID-19 Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Shionogi Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Shionogi Recent Developments
11.4 Simcere Pharmaceutical
11.4.1 Simcere Pharmaceutical Company Information
11.4.2 Simcere Pharmaceutical Overview
11.4.3 Simcere Pharmaceutical Oral Antiviral Medicines for COVID-19 Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Simcere Pharmaceutical Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Simcere Pharmaceutical Recent Developments
11.5 Frontier Biotechnologies
11.5.1 Frontier Biotechnologies Company Information
11.5.2 Frontier Biotechnologies Overview
11.5.3 Frontier Biotechnologies Oral Antiviral Medicines for COVID-19 Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Frontier Biotechnologies Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Frontier Biotechnologies Recent Developments
11.6 Kexing Biopharm
11.6.1 Kexing Biopharm Company Information
11.6.2 Kexing Biopharm Overview
11.6.3 Kexing Biopharm Oral Antiviral Medicines for COVID-19 Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Kexing Biopharm Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Kexing Biopharm Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Oral Antiviral Medicines for COVID-19 Industry Chain Analysis
12.2 Oral Antiviral Medicines for COVID-19 Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Oral Antiviral Medicines for COVID-19 Production Mode & Process
12.4 Oral Antiviral Medicines for COVID-19 Sales and Marketing
12.4.1 Oral Antiviral Medicines for COVID-19 Sales Channels
12.4.2 Oral Antiviral Medicines for COVID-19 Distributors
12.5 Oral Antiviral Medicines for COVID-19 Customers
13 Market Dynamics
13.1 Oral Antiviral Medicines for COVID-19 Industry Trends
13.2 Oral Antiviral Medicines for COVID-19 Market Drivers
13.3 Oral Antiviral Medicines for COVID-19 Market Challenges
13.4 Oral Antiviral Medicines for COVID-19 Market Restraints
14 Key Findings in The Global Oral Antiviral Medicines for COVID-19 Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Oral Antiviral Medicines for COVID-19 Market Size Growth Rate by Type, 2018 VS 2023 VS 2033 (US$ Million)
Table 2. Major Manufacturers of Lagevrio
Table 3. Major Manufacturers of Paxlovid
Table 4. Major Manufacturers of Azvudine
Table 5. Global Oral Antiviral Medicines for COVID-19 Market Size Growth Rate by Application, 2018 VS 2023 VS 2033 (US$ Million)
Table 6. Global Oral Antiviral Medicines for COVID-19 Revenue Grow Rate (CAGR) by Region: 2018 VS 2023 VS 2033 (US$ Million)
Table 7. Global Oral Antiviral Medicines for COVID-19 Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Oral Antiviral Medicines for COVID-19 Revenue by Region (2024-2033) & (US$ Million)
Table 9. Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Region (2018-2023)
Table 10. Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Region (2024-2033)
Table 11. Global Oral Antiviral Medicines for COVID-19 Sales Grow Rate (CAGR) by Region: 2018 VS 2023 VS 2033 (US$ Million)
Table 12. Global Oral Antiviral Medicines for COVID-19 Sales by Region (2018-2023) & (Units)
Table 13. Global Oral Antiviral Medicines for COVID-19 Sales by Region (2024-2033) & (Units)
Table 14. Global Oral Antiviral Medicines for COVID-19 Sales Market Share by Region (2018-2023)
Table 15. Global Oral Antiviral Medicines for COVID-19 Sales Market Share by Region (2024-2033)
Table 16. Global Oral Antiviral Medicines for COVID-19 Sales by Manufacturers (2018-2023) & (Units)
Table 17. Global Oral Antiviral Medicines for COVID-19 Sales Share by Manufacturers (2018-2023)
Table 18. Global Oral Antiviral Medicines for COVID-19 Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Oral Antiviral Medicines for COVID-19 Revenue Share by Manufacturers (2018-2023)
Table 20. Global Key Players of Oral Antiviral Medicines for COVID-19, Industry Ranking, 2021 VS 2023 VS 2023
Table 21. Oral Antiviral Medicines for COVID-19 Price by Manufacturers 2018-2023 (US$/Unit)
Table 22. Global Oral Antiviral Medicines for COVID-19 Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Oral Antiviral Medicines for COVID-19 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Antiviral Medicines for COVID-19 as of 2023)
Table 24. Global Key Manufacturers of Oral Antiviral Medicines for COVID-19, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Oral Antiviral Medicines for COVID-19, Product Offered and Application
Table 26. Global Key Manufacturers of Oral Antiviral Medicines for COVID-19, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2023) & (Units)
Table 29. Global Oral Antiviral Medicines for COVID-19 Sales by Type (2024-2033) & (Units)
Table 30. Global Oral Antiviral Medicines for COVID-19 Sales Share by Type (2018-2023)
Table 31. Global Oral Antiviral Medicines for COVID-19 Sales Share by Type (2024-2033)
Table 32. Global Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Oral Antiviral Medicines for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 34. Global Oral Antiviral Medicines for COVID-19 Revenue Share by Type (2018-2023)
Table 35. Global Oral Antiviral Medicines for COVID-19 Revenue Share by Type (2024-2033)
Table 36. Oral Antiviral Medicines for COVID-19 Price by Type (2018-2023) & (US$/Unit)
Table 37. Global Oral Antiviral Medicines for COVID-19 Price Forecast by Type (2024-2033) & (US$/Unit)
Table 38. Global Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2023) & (Units)
Table 39. Global Oral Antiviral Medicines for COVID-19 Sales by Application (2024-2033) & (Units)
Table 40. Global Oral Antiviral Medicines for COVID-19 Sales Share by Application (2018-2023)
Table 41. Global Oral Antiviral Medicines for COVID-19 Sales Share by Application (2024-2033)
Table 42. Global Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Oral Antiviral Medicines for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 44. Global Oral Antiviral Medicines for COVID-19 Revenue Share by Application (2018-2023)
Table 45. Global Oral Antiviral Medicines for COVID-19 Revenue Share by Application (2024-2033)
Table 46. Oral Antiviral Medicines for COVID-19 Price by Application (2018-2023) & (US$/Unit)
Table 47. Global Oral Antiviral Medicines for COVID-19 Price Forecast by Application (2024-2033) & (US$/Unit)
Table 48. US & Canada Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2023) & (Units)
Table 49. US & Canada Oral Antiviral Medicines for COVID-19 Sales by Type (2024-2033) & (Units)
Table 50. US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 51. US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 52. US & Canada Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2023) & (Units)
Table 53. US & Canada Oral Antiviral Medicines for COVID-19 Sales by Application (2024-2033) & (Units)
Table 54. US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 55. US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 56. US & Canada Oral Antiviral Medicines for COVID-19 Revenue Grow Rate (CAGR) by Country: 2018 VS 2023 VS 2033 (US$ Million)
Table 57. US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Country (2018-2023) & (US$ Million)
Table 58. US & Canada Oral Antiviral Medicines for COVID-19 Revenue by Country (2024-2033) & (US$ Million)
Table 59. US & Canada Oral Antiviral Medicines for COVID-19 Sales by Country (2018-2023) & (Units)
Table 60. US & Canada Oral Antiviral Medicines for COVID-19 Sales by Country (2024-2033) & (Units)
Table 61. Europe Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2023) & (Units)
Table 62. Europe Oral Antiviral Medicines for COVID-19 Sales by Type (2024-2033) & (Units)
Table 63. Europe Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 64. Europe Oral Antiviral Medicines for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 65. Europe Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2023) & (Units)
Table 66. Europe Oral Antiviral Medicines for COVID-19 Sales by Application (2024-2033) & (Units)
Table 67. Europe Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 68. Europe Oral Antiviral Medicines for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 69. Europe Oral Antiviral Medicines for COVID-19 Revenue Grow Rate (CAGR) by Country: 2018 VS 2023 VS 2033 (US$ Million)
Table 70. Europe Oral Antiviral Medicines for COVID-19 Revenue by Country (2018-2023) & (US$ Million)
Table 71. Europe Oral Antiviral Medicines for COVID-19 Revenue by Country (2024-2033) & (US$ Million)
Table 72. Europe Oral Antiviral Medicines for COVID-19 Sales by Country (2018-2023) & (Units)
Table 73. Europe Oral Antiviral Medicines for COVID-19 Sales by Country (2024-2033) & (Units)
Table 74. China Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2023) & (Units)
Table 75. China Oral Antiviral Medicines for COVID-19 Sales by Type (2024-2033) & (Units)
Table 76. China Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 77. China Oral Antiviral Medicines for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 78. China Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2023) & (Units)
Table 79. China Oral Antiviral Medicines for COVID-19 Sales by Application (2024-2033) & (Units)
Table 80. China Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 81. China Oral Antiviral Medicines for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 82. Asia Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2023) & (Units)
Table 83. Asia Oral Antiviral Medicines for COVID-19 Sales by Type (2024-2033) & (Units)
Table 84. Asia Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 85. Asia Oral Antiviral Medicines for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 86. Asia Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2023) & (Units)
Table 87. Asia Oral Antiviral Medicines for COVID-19 Sales by Application (2024-2033) & (Units)
Table 88. Asia Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 89. Asia Oral Antiviral Medicines for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 90. Asia Oral Antiviral Medicines for COVID-19 Revenue Grow Rate (CAGR) by Country: 2018 VS 2023 VS 2033 (US$ Million)
Table 91. Asia Oral Antiviral Medicines for COVID-19 Revenue by Region (2018-2023) & (US$ Million)
Table 92. Asia Oral Antiviral Medicines for COVID-19 Revenue by Region (2024-2033) & (US$ Million)
Table 93. Asia Oral Antiviral Medicines for COVID-19 Sales by Region (2018-2023) & (Units)
Table 94. Asia Oral Antiviral Medicines for COVID-19 Sales by Region (2024-2033) & (Units)
Table 95. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Type (2018-2023) & (Units)
Table 96. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Type (2024-2033) & (Units)
Table 97. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 98. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 99. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Application (2018-2023) & (Units)
Table 100. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Application (2024-2033) & (Units)
Table 101. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 102. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 103. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue Grow Rate (CAGR) by Country: 2018 VS 2023 VS 2033 (US$ Million)
Table 104. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Country (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue by Country (2024-2033) & (US$ Million)
Table 106. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Country (2018-2023) & (Units)
Table 107. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales by Country (2024-2033) & (Units)
Table 108. Pfizer Company Information
Table 109. Pfizer Description and Major Businesses
Table 110. Pfizer Oral Antiviral Medicines for COVID-19 Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Pfizer Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Pfizer Recent Developments
Table 113. Merck Company Information
Table 114. Merck Description and Major Businesses
Table 115. Merck Oral Antiviral Medicines for COVID-19 Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Merck Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Merck Recent Developments
Table 118. Shionogi Company Information
Table 119. Shionogi Description and Major Businesses
Table 120. Shionogi Oral Antiviral Medicines for COVID-19 Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Shionogi Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Shionogi Recent Developments
Table 123. Simcere Pharmaceutical Company Information
Table 124. Simcere Pharmaceutical Description and Major Businesses
Table 125. Simcere Pharmaceutical Oral Antiviral Medicines for COVID-19 Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Simcere Pharmaceutical Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Simcere Pharmaceutical Recent Developments
Table 128. Frontier Biotechnologies Company Information
Table 129. Frontier Biotechnologies Description and Major Businesses
Table 130. Frontier Biotechnologies Oral Antiviral Medicines for COVID-19 Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. Frontier Biotechnologies Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Frontier Biotechnologies Recent Developments
Table 133. Kexing Biopharm Company Information
Table 134. Kexing Biopharm Description and Major Businesses
Table 135. Kexing Biopharm Oral Antiviral Medicines for COVID-19 Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. Kexing Biopharm Oral Antiviral Medicines for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Kexing Biopharm Recent Developments
Table 138. Key Raw Materials Lists
Table 139. Raw Materials Key Suppliers Lists
Table 140. Oral Antiviral Medicines for COVID-19 Distributors List
Table 141. Oral Antiviral Medicines for COVID-19 Customers List
Table 142. Oral Antiviral Medicines for COVID-19 Market Trends
Table 143. Oral Antiviral Medicines for COVID-19 Market Drivers
Table 144. Oral Antiviral Medicines for COVID-19 Market Challenges
Table 145. Oral Antiviral Medicines for COVID-19 Market Restraints
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Oral Antiviral Medicines for COVID-19 Product Picture
Figure 2. Global Oral Antiviral Medicines for COVID-19 Market Size Growth Rate by Type, 2018 VS 2023 VS 2033 (US$ Million)
Figure 3. Global Oral Antiviral Medicines for COVID-19 Market Share by Type in 2023 & 2033
Figure 4. Lagevrio Product Picture
Figure 5. Paxlovid Product Picture
Figure 6. Azvudine Product Picture
Figure 7. Global Oral Antiviral Medicines for COVID-19 Market Size Growth Rate by Application, 2018 VS 2023 VS 2033 (US$ Million)
Figure 8. Global Oral Antiviral Medicines for COVID-19 Market Share by Application in 2023 & 2033
Figure 9. Aldult
Figure 10. Elder
Figure 11. Oral Antiviral Medicines for COVID-19 Report Years Considered
Figure 12. Global Oral Antiviral Medicines for COVID-19 Revenue, (US$ Million), 2018 VS 2023 VS 2033
Figure 13. Global Oral Antiviral Medicines for COVID-19 Revenue 2018-2033 (US$ Million)
Figure 14. Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Region in Percentage: 2023 Versus 2033
Figure 15. Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Region (2018-2033)
Figure 16. Global Oral Antiviral Medicines for COVID-19 Sales 2018-2033 ((Units)
Figure 17. Global Oral Antiviral Medicines for COVID-19 Sales Market Share by Region (2018-2033)
Figure 18. US & Canada Oral Antiviral Medicines for COVID-19 Sales YoY (2018-2033) & (Units)
Figure 19. US & Canada Oral Antiviral Medicines for COVID-19 Revenue YoY (2018-2033) & (US$ Million)
Figure 20. Europe Oral Antiviral Medicines for COVID-19 Sales YoY (2018-2033) & (Units)
Figure 21. Europe Oral Antiviral Medicines for COVID-19 Revenue YoY (2018-2033) & (US$ Million)
Figure 22. China Oral Antiviral Medicines for COVID-19 Sales YoY (2018-2033) & (Units)
Figure 23. China Oral Antiviral Medicines for COVID-19 Revenue YoY (2018-2033) & (US$ Million)
Figure 24. Asia (excluding China) Oral Antiviral Medicines for COVID-19 Sales YoY (2018-2033) & (Units)
Figure 25. Asia (excluding China) Oral Antiviral Medicines for COVID-19 Revenue YoY (2018-2033) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales YoY (2018-2033) & (Units)
Figure 27. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue YoY (2018-2033) & (US$ Million)
Figure 28. The Oral Antiviral Medicines for COVID-19 Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
Figure 29. The Top 5 and 10 Largest Manufacturers of Oral Antiviral Medicines for COVID-19 in the World: Market Share by Oral Antiviral Medicines for COVID-19 Revenue in 2023
Figure 30. Global Oral Antiviral Medicines for COVID-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2023
Figure 31. Global Oral Antiviral Medicines for COVID-19 Sales Market Share by Type (2018-2033)
Figure 32. Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 33. Global Oral Antiviral Medicines for COVID-19 Sales Market Share by Application (2018-2033)
Figure 34. Global Oral Antiviral Medicines for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 35. US & Canada Oral Antiviral Medicines for COVID-19 Sales Market Share by Type (2018-2033)
Figure 36. US & Canada Oral Antiviral Medicines for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 37. US & Canada Oral Antiviral Medicines for COVID-19 Sales Market Share by Application (2018-2033)
Figure 38. US & Canada Oral Antiviral Medicines for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 39. US & Canada Oral Antiviral Medicines for COVID-19 Revenue Share by Country (2018-2033)
Figure 40. US & Canada Oral Antiviral Medicines for COVID-19 Sales Share by Country (2018-2033)
Figure 41. U.S. Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 42. Canada Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 43. Europe Oral Antiviral Medicines for COVID-19 Sales Market Share by Type (2018-2033)
Figure 44. Europe Oral Antiviral Medicines for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 45. Europe Oral Antiviral Medicines for COVID-19 Sales Market Share by Application (2018-2033)
Figure 46. Europe Oral Antiviral Medicines for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 47. Europe Oral Antiviral Medicines for COVID-19 Revenue Share by Country (2018-2033)
Figure 48. Europe Oral Antiviral Medicines for COVID-19 Sales Share by Country (2018-2033)
Figure 49. Germany Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 50. France Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 51. U.K. Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 52. Italy Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 53. Russia Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 54. China Oral Antiviral Medicines for COVID-19 Sales Market Share by Type (2018-2033)
Figure 55. China Oral Antiviral Medicines for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 56. China Oral Antiviral Medicines for COVID-19 Sales Market Share by Application (2018-2033)
Figure 57. China Oral Antiviral Medicines for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 58. Asia Oral Antiviral Medicines for COVID-19 Sales Market Share by Type (2018-2033)
Figure 59. Asia Oral Antiviral Medicines for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 60. Asia Oral Antiviral Medicines for COVID-19 Sales Market Share by Application (2018-2033)
Figure 61. Asia Oral Antiviral Medicines for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 62. Asia Oral Antiviral Medicines for COVID-19 Revenue Share by Region (2018-2033)
Figure 63. Asia Oral Antiviral Medicines for COVID-19 Sales Share by Region (2018-2033)
Figure 64. Japan Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 65. South Korea Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 66. China Taiwan Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 67. Southeast Asia Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 68. India Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales Market Share by Type (2018-2033)
Figure 70. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 71. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales Market Share by Application (2018-2033)
Figure 72. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 73. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Revenue Share by Country (2018-2033)
Figure 74. Middle East, Africa and Latin America Oral Antiviral Medicines for COVID-19 Sales Share by Country (2018-2033)
Figure 75. Brazil Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 76. Mexico Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 77. Turkey Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 78. Israel Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 79. GCC Countries Oral Antiviral Medicines for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 80. Oral Antiviral Medicines for COVID-19 Value Chain
Figure 81. Oral Antiviral Medicines for COVID-19 Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed